Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1977 1
1981 2
1982 1
1984 3
1986 1
1987 1
1988 5
1989 1
1990 7
1991 5
1992 4
1993 4
1994 6
1995 5
1996 12
1997 9
1998 13
1999 9
2000 7
2001 5
2002 7
2003 5
2004 5
2005 5
2006 7
2007 10
2008 4
2009 6
2010 9
2011 8
2012 8
2013 19
2014 40
2015 41
2016 42
2017 37
2018 38
2019 40
2020 50
2021 60
2022 38
2023 48
2024 63
2025 42

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

662 results

Results by year

Filters applied: . Clear all
Page 1
Bacteria induce skin regeneration via IL-1β signaling.
Wang G, Sweren E, Liu H, Wier E, Alphonse MP, Chen R, Islam N, Li A, Xue Y, Chen J, Park S, Chen Y, Lee S, Wang Y, Wang S, Archer NK, Andrews W, Kane MA, Dare E, Reddy SK, Hu Z, Grice EA, Miller LS, Garza LA. Wang G, et al. Cell Host Microbe. 2021 May 12;29(5):777-791.e6. doi: 10.1016/j.chom.2021.03.003. Epub 2021 Apr 1. Cell Host Microbe. 2021. PMID: 33798492 Free PMC article.
WIHN levels and stem cell markers correlate with bacterial counts, being lowest in germ-free (GF), intermediate in conventional specific pathogen-free (SPF), and highest in wild-type mice, even those infected with pathogenic Staphylococcus aureus. Reducing skin microbiota …
WIHN levels and stem cell markers correlate with bacterial counts, being lowest in germ-free (GF), intermediate in conventional specific pat …
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Herbst RS, et al. N Engl J Med. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346. N Engl J Med. 2020. PMID: 32997907 Clinical Trial.
Overall survival (primary end point) was tested hierarchically according to PD-L1 expression status among patients in the intention-to-treat population whose tumors were wild-type with respect to EGFR mutations or ALK translocations. Within the population with EGFR and ALK …
Overall survival (primary end point) was tested hierarchically according to PD-L1 expression status among patients in the intention-to-treat …
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.
Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, Bookbinder M, Willard R, Davenport K, Bortolon E, Cadelina G, Gordon D, Pizzano J, Macaluso J, Soto L, Corradi J, Digianantonio K, Drulyte I, Morgan A, Quinn C, Békés M, Ferraro C, Chen X, Wang G, Dong H, Wang J, Langley DR, Houston J, Gedrich R, Taylor IC. Gough SM, et al. Clin Cancer Res. 2024 Aug 15;30(16):3549-3563. doi: 10.1158/1078-0432.CCR-23-3465. Clin Cancer Res. 2024. PMID: 38819400 Free PMC article.
We used biochemical and intracellular target engagement assays to demonstrate the mechanism of action of vepdegestrant, and ESR1 wild-type (WT) and mutant ER+ preclinical breast cancer models to demonstrate ER degradation-mediated tumor growth inhibition (TGI). RESULTS: Ve …
We used biochemical and intracellular target engagement assays to demonstrate the mechanism of action of vepdegestrant, and ESR1 wild …
From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.
Chen LH, Fritzer A, Hochreiter R, Dubischar K, Meyer S. Chen LH, et al. J Travel Med. 2024 Oct 19;31(7):taae123. doi: 10.1093/jtm/taae123. J Travel Med. 2024. PMID: 39255380 Free PMC article. Review.
RESULTS: In mice and non-human primate models, VLA1553 elicited high titres of neutralizing antibodies, conferred protection against wild-type chikungunya virus challenge and raised no safety concerns. A Phase 1 clinical trial of VLA1553 demonstrated 100% seroconversion am …
RESULTS: In mice and non-human primate models, VLA1553 elicited high titres of neutralizing antibodies, conferred protection against wild …
Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy.
Helms AS, Thompson AD, Glazier AA, Hafeez N, Kabani S, Rodriguez J, Yob JM, Woolcock H, Mazzarotto F, Lakdawala NK, Wittekind SG, Pereira AC, Jacoby DL, Colan SD, Ashley EA, Saberi S, Ware JS, Ingles J, Semsarian C, Michels M, Olivotto I, Ho CY, Day SM. Helms AS, et al. Circ Genom Precis Med. 2020 Oct;13(5):396-405. doi: 10.1161/CIRCGEN.120.002929. Epub 2020 Aug 25. Circ Genom Precis Med. 2020. PMID: 32841044 Free PMC article.
C10 mutant MyBP-C failed to incorporate into myofilaments and degradation rates were accelerated by 90%, while C3 and C6 mutant MyBP-C incorporated normally with degradation rate similar to wild-type. CONCLUSIONS: Truncating variants account for 91% of MYBPC3 pathogenic va …
C10 mutant MyBP-C failed to incorporate into myofilaments and degradation rates were accelerated by 90%, while C3 and C6 mutant MyBP-C incor …
Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy.
Helms AS, Davis FM, Coleman D, Bartolone SN, Glazier AA, Pagani F, Yob JM, Sadayappan S, Pedersen E, Lyons R, Westfall MV, Jones R, Russell MW, Day SM. Helms AS, et al. Circ Cardiovasc Genet. 2014 Aug;7(4):434-43. doi: 10.1161/CIRCGENETICS.113.000448. Epub 2014 Jul 16. Circ Cardiovasc Genet. 2014. PMID: 25031304 Free PMC article.
For truncating mutations in MYBPC3, the average ratio of mutant:wild-type transcripts was 1:5, in contrast to 1:1 for all sarcomere missense mutations, confirming that nonsense transcripts are uniquely unstable. ...By absolute quantification of abundance with multiple reac …
For truncating mutations in MYBPC3, the average ratio of mutant:wild-type transcripts was 1:5, in contrast to 1:1 for all sarcomere m …
EXO1 protects BRCA1-deficient cells against toxic DNA lesions.
van de Kooij B, Schreuder A, Pavani R, Garzero V, Uruci S, Wendel TJ, van Hoeck A, San Martin Alonso M, Everts M, Koerse D, Callen E, Boom J, Mei H, Cuppen E, Luijsterburg MS, van Vugt MATM, Nussenzweig A, van Attikum H, Noordermeer SM. van de Kooij B, et al. Mol Cell. 2024 Feb 15;84(4):659-674.e7. doi: 10.1016/j.molcel.2023.12.039. Epub 2024 Jan 23. Mol Cell. 2024. PMID: 38266640 Free PMC article.
EXO1 deficiency generates poly(ADP-ribose)-decorated DNA lesions during S phase that associate with unresolved DSBs and genomic instability in BRCA1-deficient but not in wild-type or BRCA2-deficient cells. Our data indicate that BRCA1/EXO1 double-deficient cells accumulate …
EXO1 deficiency generates poly(ADP-ribose)-decorated DNA lesions during S phase that associate with unresolved DSBs and genomic instability …
Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.
Brandi P, Conejero L, Cueto FJ, Martínez-Cano S, Dunphy G, Gómez MJ, Relaño C, Saz-Leal P, Enamorado M, Quintas A, Dopazo A, Amores-Iniesta J, Del Fresno C, Nistal-Villán E, Ardavín C, Nieto A, Casanovas M, Subiza JL, Sancho D. Brandi P, et al. Cell Rep. 2022 Jan 4;38(1):110184. doi: 10.1016/j.celrep.2021.110184. Cell Rep. 2022. PMID: 34986349 Free PMC article.
Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking functional lymphocytes, indicative of innate immune-mediated protection. ...
Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking func …
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD. Lane T, et al. Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Circulation. 2019. PMID: 31109193
We sought to characterize the natural history of ATTR-CM and compare outcomes and quality of life among patients with acquired and hereditary forms of the disease. METHODS: We studied 711 patients with wild-type ATTR-CM, 205 with hereditary ATTR-CM associated with the V122 …
We sought to characterize the natural history of ATTR-CM and compare outcomes and quality of life among patients with acquired and hereditar …
Stromal Cell-SLIT3/Cardiomyocyte-ROBO1 Axis Regulates Pressure Overload-Induced Cardiac Hypertrophy.
Liu X, Li B, Wang S, Zhang E, Schultz M, Touma M, Monteiro Da Rocha A, Evans SM, Eichmann A, Herron T, Chen R, Xiong D, Jaworski A, Weiss S, Si MS. Liu X, et al. Circ Res. 2024 Mar 29;134(7):913-930. doi: 10.1161/CIRCRESAHA.122.321292. Epub 2024 Feb 27. Circ Res. 2024. PMID: 38414132 Free PMC article.
RESULTS: We first found that SLIT3 transcription was increased in myocardial tissue obtained from patients with congenital heart defects that caused ventricular pressure overload. Immunostaining of hearts from WT (wild-type) and reporter mice revealed that SLIT3 is secrete …
RESULTS: We first found that SLIT3 transcription was increased in myocardial tissue obtained from patients with congenital heart defects tha …
662 results